Author

Dale Shepard

Institution: Cleveland Clinic

Observed institution: Cleveland Clinic

OpenAlex ID: A5137091421

The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.

2026 · Hans Gelderblom, Victoria Wang, et al. · Journal of Clinical Oncology · 5

Neighborhood socioeconomic disadvantage is associated with worse survival in localized extremity soft tissue sarcoma

2026 · Brian Benyamini, Riley O’Toole, et al. · BMC Cancer · 1

Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF -mutant melanoma.

2026 · Monica F. Chen, Marcus O. Butler, et al. · Journal of Clinical Oncology · 1

Management of Soft Tissue and Visceral Leiomyosarcomas

2026 · Fernando Campos, Rebecca Gladdy, et al. · JAMA Oncology

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion

2026 · Adis journals on behalf of:, Dale Shepard, et al. · Figshare

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion

2026 · Dale Shepard, Sydney Stern, et al. · Advances in Therapy

Response to: “Comment on: risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors”

2026 · Nitesh Mohan, Sunil K. Srivastava, et al. · Eye

Implementing a clinical research coordinator–led care delivery model (CRC model) in an early-phase oncology program: A pilot to streamline workflow, improve collaboration, and enhance patient-centered trial conduct.

2026 · Christina Chukri, Ryan Kolonick, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 7

H-index: 1

I10-index: